Go Pro
→ The 1934 playbook (From American Alternative) (Ad)tc pixel Free IMMP Stock Alerts

Prima BioMed (IMMP) Financials

Prima BioMed logo
$0.41 -0.03 (-5.88%)
As of 03:53 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare
Annual Income Statements for Prima BioMed

Annual Income Statements for Prima BioMed

This table shows Prima BioMed's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 6/30/2016 6/30/2017 6/30/2018 6/30/2019 6/30/2020 6/30/2021 6/30/2022 6/30/2023 6/30/2024 6/30/2025
Net Income / (Loss) Attributable to Common Shareholders		 -48 -7.20 -9.45 -13 -9.31 -22 -22 -27 -29 -40
Consolidated Net Income / (Loss)		 -48 -7.20 -9.45 -13 -9.31 -22 -22 -27 -29 -40
Net Income / (Loss) Continuing Operations		 -48 -7.20 -9.45 -13 -9.31 -22 -22 -27 -29 -40
Total Pre-Tax Income 		-48 -7.77 -9.45 -13 -9.31 -22 -22 -27 -29 -40
Total Operating Income		 -47 -7.27 -9.03 -13 -10 -15 -23 -28 -31 -43
Total Gross Profit		 -35 3.16 5.08 3.93 9.49 2.89 3.19 2.32 2.54 3.28
Total Revenue		 -35 3.16 5.08 3.93 9.50 2.90 3.26 2.34 2.57 3.31
Operating Revenue		 -35 3.16 5.08 3.93 9.50 2.90 3.26 2.34 2.57 3.31
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.01 0.01 0.06 0.01 0.02 0.02
Operating Cost of Revenue		 - - 0.00 0.00 0.01 0.01 0.06 0.01 0.02 0.02
Total Operating Expenses		 12 10 14 17 20 18 27 30 34 46
Selling, General & Admin Expense		 5.24 3.34 5.37 4.44 4.38 4.72 4.98 5.78 5.91 5.68
Research & Development Expense		 5.30 5.78 7.41 13 16 13 22 24 28 40
Total Other Income / (Expense), net		 -0.88 -0.50 -0.41 0.60 1.12 -7.31 1.19 1.04 2.58 2.38
Interest & Investment Income		 - 0.08 0.13 0.28 0.14 0.08 0.16 0.63 2.59 3.48
Other Income / (Expense), net		 -0.88 -0.58 -0.54 0.32 0.98 -7.39 1.03 0.41 -0.01 -1.10
Income Tax Expense		 - -0.57 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Basic Earnings per Share		 - ($0.40) ($4.63) ($5.29) ($0.03) ($0.05) ($0.03) ($0.03) ($0.02) ($0.03)
Weighted Average Basic Shares Outstanding		 - - 3.03B 3.39B 487.63M 748.15M 866.24M 1.19B 1.45B 1.46B
Diluted Earnings per Share		 - ($0.40) ($4.63) ($5.29) ($0.03) ($0.05) ($0.03) ($0.03) ($0.02) ($0.03)
Weighted Average Diluted Shares Outstanding		 - - 3.03B 3.39B 487.63M 748.15M 866.24M 1.19B 1.45B 1.46B
Weighted Average Basic & Diluted Shares Outstanding		 - - 3.03B 3.39B 487.63M 748.15M 866.24M 1.19B 1.45B 1.46B

Quarterly Income Statements for Prima BioMed

No quarterly income statements for Prima BioMed are available.

Annual Cash Flow Statements for Prima BioMed

This table details how cash moves in and out of Prima BioMed's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 6/30/2016 6/30/2017 6/30/2018 6/30/2019 6/30/2020 6/30/2021 6/30/2022 6/30/2023 6/30/2024 6/30/2025
Net Change in Cash & Equivalents		 9.24 0.09 -0.07 2.89 -0.84 6.20 -2.15 -0.26 14 -19
Net Cash From Operating Activities		 -8.48 -6.54 -5.76 -11 -7.50 -13 -21 -24 -23 -41
Net Cash From Continuing Operating Activities		 0.20 0.10 0.09 0.29 0.16 0.08 0.16 0.61 2.45 -56
Net Income / (Loss) Continuing Operations		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Non-Cash Adjustments To Reconcile Net Income		 - - - - - - 0.00 0.00 - -59
Changes in Operating Assets and Liabilities, net		 0.20 0.10 0.09 0.29 0.16 0.08 0.16 0.61 2.45 2.44
Net Cash From Investing Activities		 0.08 -0.01 -0.01 -0.03 -0.01 -0.01 -0.02 -0.06 -14 -25
Net Cash From Continuing Investing Activities		 0.08 -0.01 -0.01 -0.03 -0.01 -0.01 -0.02 -0.06 -14 33
Purchase of Property, Plant & Equipment		 -0.02 -0.01 -0.01 -0.03 -0.01 -0.01 -0.02 -0.06 -0.62 -0.03
Purchase of Investments		 - - - - - - - 0.00 - 33
Net Cash From Financing Activities		 19 -0.01 14 5.58 14 40 35 51 64 -0.35
Net Cash From Continuing Financing Activities		 8.97 -0.01 -0.61 2.35 -1.07 6.69 -1.83 -2.71 -0.15 -0.35
Repayment of Debt		 -1.13 - 0.00 0.00 -0.05 -0.16 -0.15 -0.14 -0.15 -0.18
Repurchase of Common Equity		 -0.21 -0.01 -0.61 -0.37 -1.02 -1.61 -1.68 -2.56 - -0.17
Effect of Exchange Rate Changes		 - - 0.46 0.28 0.09 -0.57 -0.46 1.89 26 4.42
Cash Interest Paid		 - - - - - 0.01 0.06 0.01 - 0.02

Quarterly Cash Flow Statements for Prima BioMed

No quarterly cash flow statements for Prima BioMed are available.

Annual Balance Sheets for Prima BioMed

This table presents Prima BioMed's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 6/30/2017 6/30/2018 6/30/2019 6/30/2020 6/30/2021 6/30/2022 6/30/2023 6/30/2024 6/30/2025
Total Assets		 27 35 28 32 62 71 98 135 103
Total Current Assets		 12 21 16 22 51 63 90 128 98
Cash & Equivalents		 9.41 17 12 18 46 55 82 108 44
Short-Term Investments		 - - - - - - - 0.00 0.01
Accounts Receivable		 1.69 2.54 3.62 2.28 4.60 5.78 5.30 4.91 6.49
Other Current Assets		 1.14 1.29 1.24 1.06 1.28 1.69 2.40 15 47
Plant, Property, & Equipment, net		 0.02 0.02 0.04 0.03 0.03 0.03 0.06 0.04 0.04
Plant, Property & Equipment, gross		 0.02 0.02 0.04 0.03 0.03 0.03 0.06 0.04 0.04
Total Noncurrent Assets		 15 14 12 11 10 7.82 8.26 6.79 5.14
Intangible Assets		 15 14 12 11 9.65 7.29 6.32 5.50 4.73
Other Noncurrent Operating Assets		 - - 0.00 0.14 0.54 0.53 1.94 1.29 0.41
Total Liabilities & Shareholders' Equity		 22 28 21 25 59 69 98 134 102
Total Liabilities		 2.04 2.88 3.72 2.46 4.14 5.59 6.76 8.05 8.77
Total Current Liabilities		 2.02 2.86 3.69 2.33 4.01 4.43 6.51 7.00 8.39
Accounts Payable		 1.99 2.72 3.52 2.03 3.59 3.97 6.01 6.38 6.99
Current Employee Benefit Liabilities		 - - - 0.21 0.26 0.25 - - 0.54
Other Current Liabilities		 - - 0.00 0.09 0.16 0.12 0.12 0.16 0.14
Total Noncurrent Liabilities		 4.46 7.13 7.56 6.87 2.57 1.16 0.80 1.05 0.39
Capital Lease Obligations		 - - 0.00 0.09 0.06 0.07 0.14 0.27 0.21
Noncurrent Deferred & Payable Income Tax Liabilities		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Noncurrent Employee Benefit Liabilities		 0.02 0.02 0.03 0.04 0.07 0.08 0.11 0.14 0.17
Other Noncurrent Operating Liabilities		 - - - - - - 0.00 0.01 0.01
Total Equity & Noncontrolling Interests		 20 25 17 23 55 65 91 127 94
Total Preferred & Common Equity		 20 25 17 46 55 65 91 127 94
Total Common Equity		 20 25 17 23 55 65 91 127 94
Common Stock		 150 158 154 168 235 254 297 362 358
Retained Earnings		 -178 -181 -183 -191 -206 -209 -226 -255 -292
Other Equity Adjustments		 48 48 46 46 26 20 20 20 28

Quarterly Balance Sheets for Prima BioMed

No quarterly balance sheets for Prima BioMed are available.

Annual Metrics And Ratios for Prima BioMed

This table displays calculated financial ratios and metrics derived from Prima BioMed's official financial filings.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 6/30/2016 6/30/2017 6/30/2018 6/30/2019 6/30/2020 6/30/2021 6/30/2022 6/30/2023 6/30/2024 6/30/2025
DEI Shares Outstanding		 0.00 0.00 3,026,082,669.00 3,388,598,296.00 487,630,938.00 748,152,935.00 866,239,815.00 1,187,306,209.00 - 1,460,389,575.00
DEI Adjusted Shares Outstanding		 0.00 0.00 3,026,082,669.00 3,388,598,296.00 487,630,938.00 748,152,935.00 866,239,815.00 1,187,306,209.00 - 1,460,389,575.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 0.00 0.00 0.00 -0.02 -0.03 -0.03 -0.02 - -0.03
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 0.00% 109.05% 60.56% -22.72% 141.99% -69.45% 12.17% -28.24% 9.82% 29.00%
EBITDA Growth		 0.00% 85.90% -25.98% -58.45% 27.59% -134.51% -1.05% -21.49% -14.36% -40.97%
EBIT Growth		 0.00% 83.60% -22.07% -36.27% 27.59% -134.51% -1.05% -21.49% -14.36% -40.97%
NOPAT Growth		 0.00% 84.53% -24.28% -48.01% 22.00% -41.67% -58.57% -17.89% -12.63% -37.47%
Net Income Growth		 0.00% 84.95% -31.23% -35.22% 27.10% -141.23% 1.00% -19.52% -7.29% -41.58%
EPS Growth		 0.00% 0.00% -1,057.50% -14.25% 99.38% -54.29% 47.91% -13.74% 20.13% -16.39%
Operating Cash Flow Growth		 0.00% 22.93% 11.83% -84.68% 29.60% -76.82% -57.50% -12.86% 1.31% -75.42%
Free Cash Flow Firm Growth		 0.00% 0.00% 73.43% -42.63% 23.11% -79.28% -42.42% -16.82% -78.37% -93.47%
Invested Capital Growth		 0.00% 0.00% -5.65% -10.88% -10.19% 3.23% -9.44% -13.78% 106.84% 162.72%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Income Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 0.00% 100.00% 100.00% 100.00% 99.92% 99.75% 98.04% 99.42% 99.20% 99.26%
EBITDA Margin		 0.00% -206.65% -162.14% -332.46% -99.48% -763.72% -688.01% -1,164.82% -1,212.95% -1,325.47%
Operating Margin		 0.00% -229.73% -177.82% -340.58% -109.78% -509.11% -719.71% -1,182.40% -1,212.64% -1,292.23%
EBIT Margin		 0.00% -247.99% -188.54% -332.46% -99.48% -763.72% -688.01% -1,164.82% -1,212.95% -1,325.47%
Profit (Net Income) Margin		 0.00% -227.54% -185.98% -325.41% -98.03% -774.12% -683.25% -1,138.03% -1,111.87% -1,220.26%
Tax Burden Percent		 100.00% 92.70% 100.01% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 100.00% 98.98% 98.63% 97.88% 98.54% 101.36% 99.31% 97.70% 91.67% 92.06%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% -65.96% -42.18% -68.00% -59.30% -87.36% -143.11% -190.63% -151.13% -84.97%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 19.11% -1.22% -20.24% -33.14% -42.79% -131.08% -179.94% -143.98% -71.09%
Return on Net Nonoperating Assets (RNNOA)		 0.00% -4.65% 0.41% 6.92% 12.74% 29.81% 106.04% 156.53% 124.90% 48.42%
Return on Equity (ROE)		 0.00% -70.61% -41.77% -61.08% -46.55% -57.55% -37.07% -34.10% -26.23% -36.55%
Cash Return on Invested Capital (CROIC)		 0.00% -265.96% -36.36% -56.49% -48.56% -90.54% -133.21% -175.83% -220.77% -174.69%
Operating Return on Assets (OROA)		 0.00% -29.20% -31.04% -41.39% -31.27% -47.23% -33.89% -32.24% -26.73% -36.89%
Return on Assets (ROA)		 0.00% -26.79% -30.62% -40.51% -30.81% -47.88% -33.65% -31.50% -24.50% -33.96%
Return on Common Equity (ROCE)		 0.00% -70.61% -41.77% -61.08% -46.55% -57.55% -37.07% -34.10% -26.23% -36.55%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -35.30% -38.02% -75.22% -20.22% -40.81% -34.24% 0.00% -22.54% 0.00%
Net Operating Profit after Tax (NOPAT)		 -33 -5.09 -6.32 -9.36 -7.30 -10 -16 -19 -22 -30
NOPAT Margin		 0.00% -160.81% -124.48% -238.41% -76.84% -356.38% -503.80% -827.68% -848.85% -904.56%
Net Nonoperating Expense Percent (NNEP)		 0.00% -85.07% -40.96% -47.76% -26.16% -44.57% -12.03% -10.69% -7.15% -13.88%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - -21.23% - -31.64%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.08% 0.25% 1.96% 0.58% 0.80% 0.74%
SG&A Expenses to Revenue		 0.00% 105.59% 105.67% 112.99% 46.14% 162.63% 152.94% 247.59% 230.42% 171.70%
R&D to Revenue		 0.00% 182.81% 145.76% 327.59% 163.56% 446.22% 664.81% 1,034.23% 1,081.42% 1,219.79%
Operating Expenses to Revenue		 0.00% 329.73% 277.82% 440.58% 209.70% 608.86% 817.75% 1,281.82% 1,311.84% 1,391.49%
Earnings before Interest and Taxes (EBIT)		 -48 -7.85 -9.58 -13 -9.45 -22 -22 -27 -31 -44
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -46 -6.54 -8.24 -13 -9.45 -22 -22 -27 -31 -44
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 32.41 15.89 3.43 2.34 2.01 1.89 2.52
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 106.22 29.23 4.16 2.63 2.16 1.97 2.66
Price to Revenue (P/Rev)		 0.00 0.00 0.00 140.21 38.52 65.03 46.66 78.25 93.03 71.99
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 41.54 29.86 11.91 8.88 10.72 6.74 3.80
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 137.27 36.61 49.36 29.71 43.10 51.02 58.66
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 0.00 -0.24 -0.34 -0.34 -0.38 -0.70 -0.81 -0.87 -0.87 -0.68
Leverage Ratio		 0.00 1.32 1.36 1.51 1.51 1.20 1.10 1.08 1.07 1.08
Compound Leverage Factor		 0.00 1.30 1.35 1.48 1.49 1.22 1.09 1.06 0.98 0.99
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.40% 0.11% 0.11% 0.15% 0.21% 0.22%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.40% 0.11% 0.11% 0.15% 0.21% 0.22%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 0.00% 100.00% 100.00% 100.00% 99.60% 99.89% 99.89% 99.85% 99.79% 99.78%
Debt to EBITDA		 0.00 0.00 0.00 0.00 -0.01 0.00 0.00 -0.01 -0.01 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 1.92 2.05 2.46 3.02 3.46 1.01
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 -0.01 0.00 0.00 -0.01 -0.01 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 -0.01 -0.01 0.00 -0.01 -0.01 -0.01
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 2.48 4.40 3.36 4.25 4.95 1.47
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 -0.01 -0.01 0.00 -0.01 -0.01 -0.01
Altman Z-Score		 0.00 0.00 0.00 78.79 80.98 22.45 12.16 13.13 17.00 12.00
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 0.00 6.05 7.43 4.44 9.26 12.81 14.16 13.81 18.25 11.69
Quick Ratio		 0.00 5.48 6.98 4.11 8.80 12.49 13.78 13.44 16.13 6.06
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -21 -5.45 -7.78 -5.98 -11 -15 -18 -32 -62
Operating Cash Flow to CapEx		 0.00% -128,030.06% -65,390.99% -36,892.78% -56,023.64% -113,072.92% -131,927.97% -42,734.07% -3,734.70% -135,571.31%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.00 0.12 0.16 0.12 0.31 0.06 0.05 0.03 0.02 0.03
Accounts Receivable Turnover		 0.00 1.88 2.40 1.27 3.22 0.84 0.63 0.42 0.50 0.58
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 170.10 265.94 139.02 267.60 89.50 114.39 57.26 52.59 78.91
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.02 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 194.53 151.96 286.42 113.24 432.57 582.11 865.71 726.11 628.39
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 140,162.57 138,980.15 21,630.25 134,058.58 110,759.21 100,155.61
Cash Conversion Cycle (CCC)		 0.00 194.53 151.96 286.42 -140,049.33 -138,547.59 -21,048.14 -133,192.87 -110,033.10 -99,527.23
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 0.00 15 15 13 12 12 11 9.39 19 51
Invested Capital Turnover		 0.00 0.41 0.34 0.29 0.77 0.25 0.28 0.23 0.18 0.09
Increase / (Decrease) in Invested Capital		 0.00 15 -0.87 -1.58 -1.32 0.38 -1.13 -1.50 10 32
Enterprise Value (EV)		 0.00 0.00 0.00 539 348 143 97 101 131 194
Market Capitalization		 0.00 0.00 0.00 550 366 189 152 183 239 238
Book Value per Share		 $0.00 $0.00 $0.01 $0.01 $0.01 $0.11 $0.09 $0.11 $0.11 $0.07
Tangible Book Value per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.09 $0.08 $0.10 $0.10 $0.06
Total Capital		 0.00 20 25 17 23 55 65 91 127 95
Total Debt		 0.00 0.00 0.00 0.00 0.09 0.06 0.07 0.14 0.27 0.21
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.09 0.06 0.07 0.14 0.27 0.21
Net Debt		 0.00 -9.41 -17 -12 -18 -45 -55 -82 -108 -44
Capital Expenditures (CapEx)		 -0.08 0.01 0.01 0.03 0.01 0.01 0.02 0.06 0.62 0.03
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 0.81 0.97 1.17 1.01 1.87 3.04 1.18 13 45
Debt-free Net Working Capital (DFNWC)		 0.00 10 18 13 19 47 58 83 121 90
Net Working Capital (NWC)		 0.00 10 18 13 19 47 58 83 121 90
Net Nonoperating Expense (NNE)		 15 2.11 3.12 3.42 2.01 12 5.84 7.25 6.75 10
Net Nonoperating Obligations (NNO)		 0.00 -4.96 -10 -4.01 -11 -43 -54 -82 -107 -43
Total Depreciation and Amortization (D&A)		 1.50 1.31 1.34 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 25.51% 19.18% 29.71% 10.67% 64.36% 93.38% 50.65% 496.47% 1,368.96%
Debt-free Net Working Capital to Revenue		 0.00% 322.76% 361.70% 323.62% 202.25% 1,632.99% 1,790.22% 3,571.11% 4,707.70% 2,708.06%
Net Working Capital to Revenue		 0.00% 322.76% 361.70% 323.62% 202.25% 1,632.99% 1,790.22% 3,571.11% 4,707.70% 2,708.06%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $0.00 ($0.57) ($3.36) ($5.03) ($0.04) ($0.04) ($0.02) ($0.03)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 3.03B 3.39B 487.63M 748.15M 866.24M 1.19B 1.45B 1.46B
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 ($0.57) ($3.36) ($5.03) ($0.04) ($0.04) ($0.02) ($0.03)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 3.03B 3.39B 487.63M 748.15M 866.24M 1.19B 1.45B 1.46B
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 3.03B 3.39B 487.63M 748.15M 866.24M 1.19B 1.45B 1.46B
Normalized Net Operating Profit after Tax (NOPAT)		 -33 -5.09 -6.32 -9.36 -7.30 -10 -16 -19 -22 -30
Normalized NOPAT Margin		 0.00% -160.81% -124.48% -238.41% -76.84% -356.38% -503.80% -827.68% -848.85% -904.56%
Pre Tax Income Margin		 0.00% -245.45% -185.95% -325.41% -98.03% -774.12% -683.25% -1,138.03% -1,111.87% -1,220.26%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -0.44% -0.09% -6.48% -2.92% -10.95% -7.17% -7.54% -9.65% -11.43% -0.41%

Quarterly Metrics And Ratios for Prima BioMed

No quarterly metrics and ratios for Prima BioMed are available.


Financials Breakdown Chart

Prima BioMed Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Prima BioMed's fiscal year ends in June. Their fiscal year 2025 ended on June 30, 2025.

Prima BioMed's net income appears to be on an upward trend, with a most recent value of -$40.38 million in 2025, falling from -$47.85 million in 2016. The previous period was -$28.52 million in 2024. Find out what analysts predict for Prima BioMed in the coming months.

Prima BioMed's total operating income in 2025 was -$42.76 million, based on the following breakdown:
  • Total Gross Profit: $3.28 million
  • Total Operating Expenses: $46.05 million

Over the last 9 years, Prima BioMed's total revenue changed from -$34.95 million in 2016 to $3.31 million in 2025, a change of -109.5%.

Prima BioMed's total liabilities were at $8.77 million at the end of 2025, a 9.0% increase from 2024, and a 330.3% increase since 2017.

In the past 8 years, Prima BioMed's cash and equivalents has ranged from $9.41 million in 2017 to $108.03 million in 2024, and is currently $44.31 million as of their latest financial filing in 2025.

Over the last 9 years, Prima BioMed's book value per share changed from 0.00 in 2016 to 0.07 in 2025, a change of 6.5%.


Related Companies

Financial statements for NASDAQ:IMMP last updated on 7/16/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
DOJ Admits It In Court—Your Cash Can Be Seized Without Warning
The Department of Justice recently argued in court that cash may not be legally your property - raising concer...
Priority Gold | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel